Impact of fibroblast growth factor-23 on peripheral arterial disease in type 2 diabetes mellitus: A comparative cross-sectional pilot study Tip 2 diyabetes mellitusta fibroblast büyüme faktörü-23’ün periferik arter hastalığı Üzerine etkisi: Bir karşılaştırmalı kesitsel pilot çalışma


HATİPOĞLU E. Ş., Özgür N., NİYAZOĞLU M., Süleyman Dikici A., Balcı Ekmekci Ö., Yalın S., ...Daha Fazla

Turkish Journal of Endocrinology and Metabolism, cilt.19, sa.4, ss.119-123, 2015 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2015
  • Doi Numarası: 10.4274/tjem.3179
  • Dergi Adı: Turkish Journal of Endocrinology and Metabolism
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.119-123
  • Anahtar Kelimeler: Diabetes mellitus, fibroblast growth factor-23, nephropathy, peripheral arterial disease, atherosclerosis, arterial calcification
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: To evaluate whether fibroblast growth factor-23 (FGF-23) has a common role in the pathogenesis of peripheral arterial disease (PAD) and chronic kidney disease (CKD) in type-2 diabetes mellitus (DM). Material and Method: Twenty-one patients with diabetic nephropathy composed the diabetic nephropathy (DM-NP) group and 20 subjects with DM but without NP constituted the DM group. The control group was comprised of 10 age- and gender-matched non-diabetic individuals with CKD. Results: FGF-23 levels were similar in DM-NP and CKD groups (p=0.5). Both groups had higher FGF-23 levels compared to DM group (p<0.001 and p=0.007). PAD was more common in DM than in CKD (p=0.03). In all cases involving DM (e.g., both the DM-NP and DM-groups), FGF-23 levels did not vary with arterial wall changes recorded via Doppler ultrasonography (p=0.5). Discussion: NP and PAD may be independent complications of DM. In DM, FGF-23 may be a marker of NP but not of PAD.